NYSE:WST - West Pharmaceutical Services Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $475.00
  • Forecasted Upside: 55.20 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$306.06
▼ -1.68 (-0.55%)

This chart shows the closing price for WST by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New West Pharmaceutical Services Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for WST and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for WST

Analyst Price Target is $475.00
▲ +55.20% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for West Pharmaceutical Services in the last 3 months. The average price target is $475.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 55.20% upside from the last price of $306.06.

This chart shows the closing price for WST for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 contributing investment analysts is to buy stock in West Pharmaceutical Services. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/11/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/11/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/10/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/8/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/6/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/6/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/5/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/5/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/22/2022William BlairReiterated RatingOutperformHigh
7/30/2021KeyCorpBoost Price TargetOverweight$350.00 ➝ $475.00High
11/9/2020KeyCorpInitiated CoverageOverweight$350.00High
10/13/2020StephensInitiated CoverageEqual Weight$300.00High
7/21/2020Bank of AmericaUpgradeNeutral ➝ Buy$280.00Low
4/24/2020Bank of AmericaUpgradeUnderperform ➝ Neutral$145.00 ➝ $200.00High
12/12/2019Bank of AmericaDowngradeNeutral ➝ Underperform$135.00Medium
7/26/2019Bank of AmericaUpgradeUnderperform ➝ NeutralHigh
5/1/2019Jefferies Financial GroupDowngradeBuy ➝ Hold$122.00Medium
4/23/2019William BlairInitiated CoverageOutperform ➝ Outperform$112.16Medium
4/25/2018Bank of AmericaDowngradeNeutral ➝ Underperform$85.00High
1/24/2018The Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$110.00Low
10/27/2017Wells Fargo & CompanyBoost Price TargetOutperform$105.00 ➝ $112.00N/A
10/17/2017Bank of AmericaDowngradeBuy ➝ Neutral$98.00N/A
10/3/2017StephensInitiated CoverageEqual ➝ Equal Weight$99.00Medium
9/15/2017Jefferies Financial GroupUpgradeHold ➝ Buy$96.00 ➝ $115.00High
(Data available from 7/6/2017 forward)

News Sentiment Rating

0.69 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 7 very positive mentions
  • 14 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
12/7/2021
  • 5 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
1/6/2022
  • 3 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/5/2022
  • 9 very positive mentions
  • 24 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
3/7/2022
  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/6/2022
  • 4 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/6/2022
  • 3 very positive mentions
  • 19 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
6/5/2022
  • 4 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/5/2022

Current Sentiment

  • 4 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
West Pharmaceutical Services logo
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Read More

Today's Range

Now: $306.06
Low: $298.12
High: $306.81

50 Day Range

MA: $303.18
Low: $280.61
High: $332.36

52 Week Range

Now: $306.06
Low: $275.89
High: $475.35

Volume

412,312 shs

Average Volume

443,863 shs

Market Capitalization

$22.67 billion

P/E Ratio

34.01

Dividend Yield

0.23%

Beta

1.13

Frequently Asked Questions

What sell-side analysts currently cover shares of West Pharmaceutical Services?

The following equities research analysts have issued reports on West Pharmaceutical Services in the last year: KeyCorp, StockNews.com, and William Blair.
View the latest analyst ratings for WST.

What is the current price target for West Pharmaceutical Services?

0 Wall Street analysts have set twelve-month price targets for West Pharmaceutical Services in the last year. Their average twelve-month price target is $475.00, suggesting a possible upside of 55.2%.
View the latest price targets for WST.

What is the current consensus analyst rating for West Pharmaceutical Services?

West Pharmaceutical Services currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe WST will outperform the market and that investors should add to their positions of West Pharmaceutical Services.
View the latest ratings for WST.

How do I contact West Pharmaceutical Services' investor relations team?

West Pharmaceutical Services' physical mailing address is 530 HERMAN O. WEST DRIVE, EXTON PA, 19341. The medical instruments supplier's listed phone number is (610) 594-2900 and its investor relations email address is [email protected] The official website for West Pharmaceutical Services is www.westpharma.com. Learn More about contacing West Pharmaceutical Services investor relations.